Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID06635980

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Non-Metastatic Breast Cancer Before or After Breast Surgery for Different Breast Cancer Risk Groups

Led by Mayo Clinic · Updated on 2025-12-12

120

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how well hypofractionated radiotherapy given before or after breast surgery works for patients with different types of non-metastatic breast cancer. This phase II trial aims to compare the safety and side effects of preoperative versus postoperative radiation therapy and to study various outcomes including tumor response, wound healing, and long-term cancer control. Radiation therapy is an important part of breast cancer treatment, and this study explores how delivering it in larger doses over fewer treatments may reduce side effects and improve results. Participants are assigned to one of two groups: one group receives standard chemotherapy followed by hypofractionated radiation therapy before breast surgery, while the other group has chemotherapy and surgery first, then radiation therapy. Radiation therapy is given once daily for a total of five treatments. Throughout the study, patients undergo imaging tests including CT, MRI, PET, digital mammography, and ultrasound. Biopsies and optional blood and tissue samples are also collected to study tumor biology and treatment effects. During the study, patients are monitored at several time points including 16 weeks, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after treatment begins. Researchers assess adverse events related to radiation, wound healing complications, cancer control, patient-reported outcomes, and cosmetic results. They also analyze tumor mutations and immune responses before and after treatments. This thorough follow-up helps evaluate both the safety and the effectiveness of the radiation timing approaches in breast cancer care.

CONDITIONS

Brief Title

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histological confirmation of breast cancer
  • Clinical stage T1-T4 N0-3 M0
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Ability to provide informed consent approved by Institutional Review Board
  • Ability to complete all mandatory tests listed in the trial
  • Willingness to return to the enrolling institution for follow-up
  • Indications for radiotherapy for breast cancer
Not Eligible

You will not qualify if you...

  • Medical contraindication to radiation therapy
  • Severe active co-morbid systemic illnesses or other severe concurrent disease
  • Uncontrolled illness including infection, heart failure, unstable angina, arrhythmia, or psychiatric/social issues
  • Active systemic lupus or scleroderma
  • Pregnancy
  • Women of childbearing potential unwilling to use adequate contraception
  • Previous radiation to the same breast or chest wall
  • Recurrent breast cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Participants undergo mandatory tests including biopsies and imaging to confirm eligibility.

Treatment

Duration - Approximately 10 weeks from start of radiotherapy to surgery in Arm I; chemotherapy and surgery followed by radiotherapy in Arm II, total duration varies.

Participants receive standard chemotherapy and hypofractionated radiotherapy either before or after breast surgery depending on their assigned arm.

Radiotherapy involves 5 daily treatments; participants also undergo multiple imaging visits including CT, MRI, PET, CEDM, and ultrasound throughout treatment.

Follow-up

Duration - Up to 5 years after treatment completion

Participants are monitored for adverse events, disease control, and patient-reported outcomes after completion of treatment.

Follow-up visits occur at 16 weeks, 6 months, 12 months, 24 months, 36 months, 48 months, and 5 years.

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

3D Ultrasound Imaging of the Axillary Lymph Nodes in Breast ...

Breast Carcinoma

Actively Recruiting

1 location

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone R...

Anatomic Stage 0 Breast Cancer AJCC v8

Actively Recruiting

1 location

Patient Reported Outcomes Post-Mastectomy and In-house 3D-pr...

Breast Carcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here